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Title: 
 
MR imaging of tenosynovial giant cell tumor: additional value of a T2*- 
weighted gradient echo sequence 
 
 
Background/Purpose: 
 
To evaluate the role of a T2*-weighted gradient echo (GRE) sequence added to 
a standard MR imaging protocol in assessing the iron content of tumor tissue 
and the extent of joint involvement in patients with tenosynovial giant cell tumor 
(TGCT). 
 
 
Methods and Materials: 
 
MR studies of 58 patients (mean age: 36,7 years; 35 female, 23 male) with 
histologically proven TGCT (knee: n=44, hip: n=5, ankle: n=5, elbow: n=1, 
tarsus: n=1, tendon sheath: n=2) obtained prior to surgical resection were 
retrospectively analyzed. All examinations were performed according to a 
standardized protocol which in addition to T1-, T2-weighted and CE SE/TSE 
sequence a T2*-weighted GRE sequence is included. Standard and GRE images 
were separately analyzed by three independent observers with regard to 1) 
relative iron content of tumor tissue as determined by the distribution and extent 
of blooming (susceptibility) artifacts (0-absent, 1-focal (<30%), 2- 
moderate/confluent (30-70%), 3-massive/diffuse (>70%)) and 2) the 
identification of tumor tissue on GRE images in joint compartments which 
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appeared uninvolved on images of standard sequences. Intraoperative and 
histologic findings served as the standards of reference. All histologic specimens 
were reviewed and iron content was graded corresponding to the above 
mentioned classification by an experienced pathologist. 
 
 
Results: 
 
59% of the lesions were classified (WHO 2013) as localized and 41% as diffuse 
TGCTs. On histologic review, the iron content was graded as follows: 0: n=2, 1: 
n=13, 2: n=29, 3: n=14. The diagnostic accuracy of GRE images in assessing the 
iron content of tumor tissue accordingly was 88%, 79% and 81% with K values 
of 0.812, 0.683 and 0.715 for observer 1, 2, and 3 respectively. Interobserver 
agreement was excellent with kappa values ranging from 0.843 to 0.905. 
Overall, iron deposits were depicted on histopathology in 96.5% and on MR 
images in 93-96,5% of TGCTs. On GRE images the observers diagnosed 
involvement of joint compartments not seen on standard images alone in 6/58 
(10%), 6/58 (10%), and 5/58 (8%) of cases. 
 
 
Conclusions: 
 
A T2*-weighted GRE sequence added to a standard MR protocol allows 
accurate and reproducible quantification of iron content in TGCTs. Due to the 
high incidence of iron deposits in these synovial lesions, this ability together 
with typical MR findings on T1 and T2 weighted images might be of help to 
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establish the diagnosis more confidently. Furthermore, GRE images depict 
tumor manifestations in joint compartments that can appear uninvolved on 
standard images and thus, are helpful in planning of surgical treatment. 
 
 
Abbreviations: 
 
TGCT: Tenosynovial giant cell tumor 
PVNS: Pigmented villonodular synovitis 
GRE: Gradient echo 
MR: Magnetic Resonance 
 
WHO: World Health Organisation 
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INTRODUCTION 
 
 
 
 
Tenosynovial giant cell tumor (TGCT) has been classified as a neoplastic lesion 
from the group of the so called fibrohystiocytic tumours by the World Health 
Organization (WHO) in 2013 [1]. These benign lesions usually arise from the 
synovium of the joints, bursae and tendon sheath and can be subdivided 
according to their location, growth pattern and biologic behaviour into localized 
and diffuse types [1,2]. The localized type of TGCT occurs as a circumscribed 
tumor within tendon sheaths or joints, most often in the digits, knee, ankle and 
wrist [2,3]. The diffuse type of TGCT (former PVNS) shows a more aggressive 
growth pattern and predominantly affects the knee joint (73-80% of cases) 
followed in decreasing frequency by the hip, the ankle, the shoulder and the 
elbow joint [1,4-6]. 
Histologically, TGCT are characterized by the presence of a fibrous stroma with 
different proportions of mononuclear cells, multinucleate giant cells, 
macrophages and siderophages. Hemosiderin deposits in variable amounts 
represent another typical feature on pathologic examination [1,6]. 
MR imaging findings of intra- and extraarticular TGCT have been described in 
various articles and book chapters [3,7-22]. Some authors suggested the use of 
T2*-weighted gradient echo (GRE) sequences in order to depict susceptibility 
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artifacts (“blooming”) caused by the iron content of the tumor tissue and thus, to 
narrow the differential diagnosis [3,14-23]. However, little is known about the 
true frequency of this finding in the localized and diffuse type, and its value for 
defining the extent of the disease prior to surgery has not been determined in 
radiologic studies. Furthermore, it remains unclear whether a direct correlaton of 
MR findings and histologic quantification of hemosiderin deposition exists. 
The purpose of our study was to evaluate the role of a T2*-weighted gradient 
echo (GRE) sequence added to a standard MR imaging protocol in assessing the 
iron content of tumor tissue and the extent of joint involvement in patients with 
tenosynovial giant cell tumor (TGCT). 
 
 
MATERIALS AND METHODS 
 
 
 
 
Study population 
 
 
 
The study was approved by our institutional review board. The requirement for 
informed consent was waived. To identify patients, the radiologic data base of 
the musculoskeletal tumor center at our institution was searched from January 
2002 to December 2013 using the key words “tenosynovial giant cell tumor “, 
“TGCT”, “giant cell tumor of the tendon sheath”, “pigmented villonodular 
synovitis”, “PVNS”, and “pigmented villonodular tenosynovitis”. The initial 
search identified a total of 301 patients. All diagnoses were cross-checked with 
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the pathology records of our institution. Inclusion criteria for the study 
population were as follows: 
a) availability of a detailed pathology report from our institution with the final 
diagnosis of TGCT(PVNS), 
b) MR examination performed at our institution with a standardized protocol 
which in addition to T1-, T2-weighted and CE SE/TSE sequences included a 
T2*-weighted GRE sequence, 
c) surgical treatment either by arthroscopic synovectomy or open total 
synovectomy performed at our Institution. 
Exclusion criteria were previous surgery (including prior biopsies) or radiation 
therapy, recurrent lesions, and incomplete MR examinations. 
 
 
MR imaging 
 
 
 
MR imaging was performed on 1.5 T systems (Magnetom Avanto, Siemens 
Medical Solutions, Erlagen Germany; Gyroscan NT Intera, Philips Medical 
systems, Best, The Netherlands) in 44 patients and on 3 T systems (Magnetom 
Verio, Siemens Medical Solutions; Ingenia, Philips Medical systems) in 14 
patients. Depending on the site of the tumor, different dedicated surface coils 
and flexible coils were utilized. Contrast-enhanced images were obtained 
following the intravenous administration of a standard dose (0.1 mmol per 
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kilogram of body weight) of gadopentate dimeglumine (Magnevist; Bayer 
healthcare, Berlin Germany). 
Parameters for all pulse sequences are presented in Table 1. 
 
 
 
Image analysis 
 
 
 
MR examinations were retrospectively and independently reviewed by three 
radiologists (K.W., S.W., D.M.) with 20, 15, and 3 years of experience in 
muskuloskeletal radiology, respectively. The three observers knew beforehand 
that all patient had pathologically confirmed TGCT (PVNS) but were unfamiliar 
with the cases. The image material was presented in random order and did not 
contain any patient information. Standard and GRE images were analyzed 
separately. At first, the three observers were asked to evaluate only the standard 
images. They had to describe the localisation (specific joint, tendon sheath, or 
bursa) and the manifestation type (localized or diffuse) of the disease. Whereas 
the localized type is characterized by a circumscribed (solitary) nodule with 
otherwise normal synovial structures, the diffuse type was diagnosed if more 
than one nodule and/or a more diffuse proliferation of synovial tissue was seen. 
The size of the lesions had to be determined by measuring the maximum 
diameter of the nodule (localized type) or by measuring the maximum length of 
the entire synovial mass (diffuse type). Measurements were performed with use 
of the integrated PACS measurement function. The predominant signal intensity 
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of the lesions was compared to that of muscle tissue on T1 weighted and to that 
of fat on T2 weighted MR images (without fat suppression) and graded as hypo-, 
iso- or hyperintense accordingly. The readers described the signal intensity of 
the tumor tissue on T1- and T2 weighted images as homogeneous, if all portions 
of the lesion had more or less the same signal intensity, and as inhomogeneous if 
the signal intensity varied among different portions of the lesion. The relative 
contrast enhancement of the tumor tissue was graded as absent, mild, moderate 
or marked and described as homogeneous, if the entire lesion showed the same 
amount of contrast enhancement, or as inhomogeneous if the grade of 
enhancement varied among different portions of the lesion. 
Thereafter, the observers were asked to assess the extent and distribution of 
susceptibility artifacts on GRE images. The extent was graded as absent, focal, 
moderate/confluent or massive/diffuse. Focal susceptibility artifacts were small 
isolated areas of signal void within the tumor tissue. In contrast, 
moderate/confluent artifacts represented larger areas of signal void which could 
be confluent but did not extend over the entire mass. Massive/diffuse artifacts 
covered major portions of the tumor tissue with hardly any uninvolved areas. 
Furthermore, the three observers analyzed the GRE images with a view to the 
identification of tumor tissue in joint compartments which appeared uninvolved 
on images of standard sequences (evidence of susceptibility artifact on GRE 
sequences with no obvious correlate on standard sequences). Intraoperative and 
histologic findings served as the standard reference. 
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Finally, the three observers evaluated the entire image sets for the presence of 
pressure erosions of bone, subchondral cysts, and bone marrow edema. A 
pressure erosion of bone was diagnosed if the bone immediately adjacent to the 
tumor or to a portion of the mass showed a well defined defect with a contour 
that followed the outer contour of the tumor. Subchondral cysts were defined as 
well-defined bone defects in the subchondral area which were either filled with 
fluid or with tumor tissue and thus, either exhibited signal intensities equivalent 
to those of water or to those of the extraossoeus component of the TGCT. Bone 
marrow edema was diagnosed, if the bone marrow adjacent to the tumor showed 
abnormal areas of high T2-weighted and decreased T1-weighted signal intensity. 
On T1-weighted images, the signal intensity had to be lower compared with 
normal fatty bone marrow and brighter compared with muscle tissue (in contrast 
to bone marrow replacement). The trabecular bone structure had to be preserved, 
and the margins to adjacent normal bone marrow were ill-defined. 
Image quality was subjectively assessed by one observer by using a three point 
scale (excellent; good; poor). 
 
 
Histopathologic Analysis 
 
 
 
Fifty-eight cases of TGCT were included in the study. For histopathologic 
evaluation, specimen were fixed in 10% neutral buffered formalin, routinely 
processed and embedded in paraffin. 5 micron sections were stained with H&E 
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for routine evaluation and Prussian blue staining for evaluation of iron 
deposition. All slides were reviewed by a musculoskeletal pathologist (M.S.) 
with 6 years of experience in muskuloskeletal pathology. Diagnosis of TGCT 
(localized or diffuse type) was confirmed according to the WHO Classification 
of Tumors of Soft Tissue and Bone in all 58 patients. Iron deposition in the 
lesions was quantified in a four-tiered scale: grade 0 = no iron deposition, grade 
1 = dot-like iron deposition (< 30% of tumor tissue), grade 2 = confluent iron 
deposition (30%-70% of tumor tissue), grade 3 = diffuse iron deposition (> 70% 
of tumor tissue). In cases of inhomogeneous staining, the grade, which was 
predominant in the tumor tissue was taken into the statistical evaluation. 
 
 
Statistical Analysis 
 
 
 
For categorical data absolute and relative frequencies are presented, quantitative 
measures are summarized by median, minimum, and maximum or mean and 
standard deviation. For assement of agreement between ratings and gold 
standard absolute and relative frequencies of concordance between rating and 
gold standard are presented with exact 95% confidence interval for the 
diagnostic accuracy. Additionally, weighted kappa values were estimated to 
evaluate each reader’s agreement with the gold standard. Weighted kappa values 
are also presented for pairwise assessment of interrater agreement. Statistical 
analyses were performed with SAS version 9.3 and SPSS version 23. 
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RESULTS 
 
 
 
 
Study Population 
 
 
 
A total of 301 consecutive MR examinations were identified between January 
2002 and December 2013. Of these 301 MR examinations, 243 were not 
included in the study group due to our inclusion and exclusion criteria. 
Recruitment of patients and the reasons for and numbers of exclusion are 
displayed in a flowchart in Fig. 1. 
58 patients (23 male, 35 female) met the inclusion criteria and were included in 
the study. The patient mean age was of 36.7 years with a standard deviation of 
13.9 years. The sites of involvement of the 58 patients included MR 
examinations of 44 knee joints, 5 hip joints, 5 ankle joints, 1 elbow joint, 1 
flexor tendon sheath of the third finger, 1 intratarsal joint and 1 flexor hallucis 
longus tendon sheath. 
The MR examinations of included patients were predominantly performed at 1.5 
T (77.5%). Only 14 of 58 (22.5%) patients underwent MR investigation with  
the 3-T system. 
The indications to undergo MR examination were either a slowly progressive 
pain with swelling (n=54) or decreased range of motion of the joint affected 
with joint effusion (n=37), 
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Image analysis 
 
 
 
The lesions were localised in joints (n=56) or in tendon sheats (n=2). Bursae 
were additionally affected by the synovial profileration in the diffuse form of 
TGCT in 18 cases. Thirty-four (59%) lesions were classified as localized forms 
and twenty-four (41%) as diffuse TGCTs. The maximum diameter of the nodule 
(localized type) measured from 1.7 cm to 6.1 cm and the maximum length of the 
entire synovial mass (diffuse type) ranged from 2.7 cm to 14 cm. 
On T1-weighted images the predominant signal intensity of the synovial 
proliferation was mainly classified as isointense and generally as homogenous. 
On T2-weighted images the three readers evaluated the synovial lesions as 
hypointense in all the patients 100%(58/58) and as inhomogeneous in the 
majority of lesions. The relative contrast enhancement of the tumor tissue was 
mainly graded as marked or moderate of our scale and described as 
inhomogeneous (Table 2). 
Overall, iron deposits were seen on histopathology of TGCTs in 56/58 (96.5%) 
patients and on MR images in 56/58 (96.5%), 55/58 (94.8%) and 54/58 (93.1%) 
for observer 1, 2, and 3 respectively. The signal void caused by hemosiderin 
deposition in the tumorous mass was assessed as a grade 3 in 13/58 (22.4%), 
14/58 (24.1%) and 15/58 (25.8%) patients, as a grade 2 in 29/58 (50%), 25/58 
(43.1%), and 25/58 (43.1%) patients, as a grade 1 in 14/58 (24.1%), 16/58 
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(27.5%) and 14/58 (24.1%) patients and no signal void was described in 2/58 
(3,4%), 3/58 (5,1%) and 4/58 (6.8%) cases. The histological evaluation 
quantified the iron deposition of the tissue specimen as a grade 3 in 14/58 
(24.1%), a grade 2 in 29/58 (50%), a grade 1 in 13/58 (22.4%) and showed no 
evidence of iron deposition in 2/58 (3.4%) cases (Figs 2 - 4). 
The observers main tendency was to underrate rather than overrate the iron 
quantification with percentage values ranging from 6.9% (4 patients) to 13.8% 
(8 patients). Considering the histological evaluation of the iron content of the 
lesions as the reference standard the diagnostic accuracy of T2*-weighted GRE 
images in assessing the iron content of tumor tissue was 88% (95% confidence 
interval: 77% to 95%), 79%, (67% to 89%) and 81% (69% to 90%). The 
weighted Kappa value for the correlation of the radiological and the 
histopathological grading was consistent with values of 0.812, 0.683 and 0.715 
for observer 1, 2 and 3 respectively. The Interobserver agreement of the 
radiological evaluation of the extent and distribution of the blooming artifact 
was substantial with weighted kappa values ranging from 0.843 to 0.905 (Table 
3). 
On GRE images the three observers diagnosed involvement of joint 
compartments not seen on standard images alone in 6/58 (10.3%), 6/58 (10.3%), 
and 5/58 (8.6%) of cases, respectively (Fig 5). The observers agreed in four 
patient and described tumor tissue in the posterior region of the knee joint in two 
patients, posterior to the medial meniscus in one patient and in the dorsal aspect 
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of the tibiotalar joint, regions which appeared uninvolved on standard images. 
The findings assessed on T2* GRE images changed the radiological diagnosis 
from that of a focal to a diffuse TGCT in six (10.3%), five (8.6%) and four 
(6.8%) cases for observer 1, 2 and 3 respectively. Intraoperative and histologic 
findings served to verify the locations assessed by the radiologist. The depiction 
of tumor tissue in joint compartments which appeared uninvolved on standard 
images was considered helpful in planning of surgical treatment changing the 
synovectomy approach. 
Evaluating the entire set of images evidence of pressure bone erosions was 
described in 23/58(39.6%), 22/58(37.9%) and 21/58(36.2%) patients, of 
subchondral cyst 8/58(13.7%), 12/58(20.6%) and 8/58(13.7%) patients and bone 
marrow edema in 1/58(1.7%), 4/58(6.8%) and 2/58(3.4%) patients (Fig. 6). 
Image quality was assessed as excellent in 33(56.8%) and good in 25(43.1%) 
examinations by observer 1. 
 
 
Histopathology 
 
 
 
In all fifty-eight cases surgical tumor resection was performed at our Institution 
between 2002 and 2013. Histopathologic analysis of resected specimen showed 
TGCT according to the criteria of the WHO classification of Tumors of Soft 
Tissue and Bone in all cases [1]. 
 15 
According to the four-tiered scale, iron deposition was quantified. Iron was 
detected either in macrophages or diffuse within tumor stroma. We found iron 
staining in > 70% of tumor tissue (grade 3) in 14/58 (24.1%) cases, confluent 
iron staining in 30-70% of tumor tissue (grade 2) in 30/58 (51.7%) cases and 
dot-like iron staining in < 30% of tumor tissue (grade 1) in 12/58 (20.7%) of 
cases. No iron staining was found in 2/58 (3.4%) cases. (Figs 2 - 4 HE, grade 2, 
3, 4) 
 
 
Discussion 
 
 
 
In the present study we have demonstrated that in patients with TGCT the 
blooming artifact sign depicted on T2* GRE sequence is accurate in the 
evaluation of hemoglobin iron content with histopathological analysis as a 
reference standard. Another important result of our study was that a T2* GRE 
sequence added to a standard MR protocol is useful in assessing the extent of 
joint involvement in patients with TGCT. 
A total of 58 patients with histologically proven TGCT were evaluated. Most of 
the lesions were located in the knee joint (72.4%) clearly outnumbering those in 
other localisations [4,5]. Furthermore, the mean age of the patients (36.7) and 
the sex distribution with a prevalence of female patients (60%) are similar to 
those of previous studies [4,5,22]. Therefore, our study population is comparable 
to other study populations and can be regarded as representative. 
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In accordance with other studies, the tumors included in our series typically 
showed homogeneous intermediate to low SI compared to muscle on T1 
weighted images [3,7-22]. In few patients MR examinations depicted areas of 
high signal intensity that, as described by other authors, might represent lipid- 
laden areas [15-18,24]. Due to the shortening of T2 relaxation time caused by 
hemosiderin intermediate to low signal intensity also predominates on T2- 
weighted MR images [3,7-22]. This effect is accentuated at higher field strength 
[15,17,18]. In our series all lesions were assessed as hypointense compared to  
fat on T2-weighted images. Contrast-enhancement is a typical but variable 
feature of TGCT [3,8,15-22]. Almost all lesions in our series showed a marked 
or moderate degree of enhancement and its pattern was mainly diagnosed as 
inhomogenous. 
On MR examinations, GRE sequences are sensitive to magnetic field 
inhomogeneity caused by magnetic susceptibility differences between tissues. 
Magnetic field inhomogeneities generally occur at the interface among tissues 
with different magnetic susceptibilities and causes the susceptibility artifact 
reported in terms of T2* signal decay [23]. On gradient-echo images in patients 
affected by TGCT the signal void is particularly evident with an enlargement of 
the low-signal-intensity areas (“blooming artifact”) caused by the magnetic 
susceptibility artifact [17,18,21,22]. Hemosiderin a breakdown product of 
hemoglobin in variable amounts represents a typical feature of TGCT on 
pathologic examination [6]. Multinucleate giant cells derived from macrophages 
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and synovial lining cells may also contain hemosiderin [6]. Evidence of 
blooming artifact was assessed in almost all the patients in this study. The three 
readers reported no signal void on T2* GRE images of two localised TGTTs. 
Correspondingly, histological analysis showed no evidence of iron staining in 
these lesions. The histological report assessed evidence of iron deposits in 
96.5% (56/58) of the patients. Due to the high incidence of iron deposits of these 
synovial lesions, evidence of iron deposits on T2* GRE images together with 
classical MR findings on T1 and T2 weighted images might be of help to 
establish the diagnosis of TGCT more confidently. Therefore a T2* GRE should 
be added to a standard tumor imaging protocol if a synovial tumor (intraarticular 
or tenosynovial) is seen on standard images. 
In our study the agreement between observers and histopathologic analysis in 
assessing the quantification of iron content of the tumor lesion was consistent. 
The observers tended to underestimate rather than overestimate the evaluation of 
the hemosiderin content of the synovial proliferation. 
Treatment of TGCT is required to avoid destruction and progressive loss of 
function of the joint involved (in diffuse intraarticular form) or the tendon or 
bursa (in localized extraarticular disease) [26]. Surgical excision is the preferred 
treatment for all forms of TGCT [18,26,30]. The localised form of TGCT of the 
knee is treated arthroscopically through standard portals (anteromedial, 
anterolateral, and superomedial) while the diffuse form of TGCT requires 
specialised arthroscopic portals (posteromedial and posterolateral) or an open 
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surgical resection [28-30]. Regardless the surgical approach, complete resection 
of tumor tissue is required to reduce the likelihood of recurrence [18,27,28,30]. 
In the present study all patients underwent surgical resection either by 
arthroscopic or open surgical procedures. The depiction of additional areas of 
involvement on T2* GRE images changed the radiological diagnosis from that 
of a focal to a diffuse form of TGCT in only a small number of patients but was 
helpful for planning of surgical treatment in these cases. To our knowledge, few 
studies evaluated the tumor extent and the involvement of the joint by MR 
Imaging [20-22]. Kitagawa and coworkers [20] assessed the accuracy of MR 
imaging in the evaluation of the tumor size and the degree of extent around the 
phalanx which can effect the planning of the surgical procedure. Eckhardt et al. 
[21] assessed in pediatric patients a better estimate of the disease’s extent in 
gradient-echo imaging. Cheng et al. [22] demonstrated in 23 patients that MR 
imaging is valuable in depicting the extent of the lesions. 
In TGCT bone changes begin with bone erosion, often near the chondroosseous 
junction, with subsequent extension of the process and formation of 
juxtaarticular cysts surrounded by fibrous tissue [6]. Pressure erosions of bone 
occur more frequently in the hip and shoulder [15] than in the knee joint 
[6,15,16]. We assessed bone erosions in 25% of the patients with a substantial 
agreement between readers. Bone erosions of the knee joint were described in at 
least the 30% of the patients by the observers. The frequency of osseous 
erosions in our study population was higher compared to prior studies 
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[4,5,22,25]. Cheng and coworkers [22] assessed evidence of bone marrow 
edema in 10 of the 23 patients analyzed. In our series bone marrow edema was 
reported in a few patients with no specific localisation. Hughes and coworkers 
[17] reported bone erosion or subchondral cyst (62% of cases), edema in the 
adjacent bone (23 % of cases) as additional MR imaging findings of diffuse 
intraarticular PVNS. Compared to Hughes et al. [17] in our study subchondral 
cysts were reported mainly in knee affected by TGCT in a lower percentage. 
Several limitations of our study should be considered. This study was limited by 
its retrospective nature and bias in that the three reviewers of the MR images 
knew beforehand that all patients had pathologically confirmed TGCT. No other 
synovial lesions were included in the study. This factor may have increased the 
sensitivity of detection of each MR findings. The three readers had different 
levels of experience. No one to one comparison histology/MR was performed. 
Finally, the sample study in our study is relatively small. 
In summary, a T2*-weighted GRE sequence added to a standard MR protocol 
allows accurate and reproducible quantification of iron content in TGCTs. Due 
to the high incidence of iron deposits in these synovial lesions, this ability 
together with typical MR findings on T1 and T2 weighted images might be of 
help to establish the diagnosis more confidently. GRE images depict tumor 
manifestations in joint compartments that can appear uninvolved on standard 
images and thus may be helpful in planning the surgical treatment. 
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Table 1. 
Parameters of MRI sequences. 
      
Sequence and Field Strenght Repetition Time 
(msec) 
Echo Time 
(msec) 
Flip Angle FOV Section Thickness In-Plane 
Resolution 
Coronal or sagittal 
T1W TSE* pre/post Gd 
      
1.5 T 413 - 929 14 – 28,8 90 160 - 180 3 < 0.5 x 0.5 
3.0 T 511 - 989 12 – 21,2 180 160 - 200 3 < 0.5 x 0.5 
Axial or sagittal 
T2W TSE 
      
1.5 T 3750 - 8620 83 - 113 180 160 - 180 3 - 5 < 0.5 x 0.5 
3.0 T 2688 - 7529 85 - 120 159 160 - 200 3 - 5 < 0.5 x 0.5 
Axial fat-saturated 
T1W TSE post Gd 
      
1.5 T 513 - 886 10 - 20 90 160 - 180 3 - 5 < 0.5 x 0.5 
3.0 T 519 - 1020 13 – 21,2 180 160 - 200 3 - 5 < 0.5 x 0.5 
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Coronal or sagittal 
T2* GRE 
      
1.5 T 413 - 929 14 – 28,8 25 160 - 180 3 < 0.7 x 0.6 
3.0 T 386 - 783 9,21 – 19,9 20 160 - 200 3 < 0.8 x 0.8 
Note. T1W = T1 weighted, T2W = T2 weighted, TSE = turbo spin echo, GRE = gradient echo, Gd = intravenous gadolinium application 
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Table 2. MR characteristics of the TGCT. 
 
 
T1 weighted signal Reader 1 Reader 2 Reader 3 
Hyperintense 1.7% (1/57) 1.7% (1/57) 5.2% (3/57) 
Isointense 87.7% (50/57) 82.4% (47/57) 84.2% (48/57) 
Hypointense 10.5% (6/57) 15.7% (9/57) 10.5% (6/57) 
Homogeneous 78.9% (45/57) 63.1% (36/57) 61.4% (35/57) 
Inhomogeneous 21% (12/57) 36.8% (21/57) 38.5% (22/57) 
T2 weighted signal Reader 1 Reader 2 Reader 3 
Hyperintense 0% (0/58) 0% (0/58) 0% (0/58) 
Isointense 0% (0/58) 0% (0/58) 0% (0/58) 
Hypointense 100% (58/58) 100% (58/58) 100% (58/58) 
Homogenous 43.1% (25/58) 39.6% (23/58) 37.9% (22/58) 
Inhomogenous 56.8% (33/58) 60.3% (35/58) 62.1% (36/58) 
Contrast enhancement Reader 1 Reader 2 Reader 3 
Marked 27.5% (16/57) 57.8% (33/57) 56.1% (32/57) 
Moderate 59.6% (34/57) 24.5% (14/57) 29.8% (17/57) 
Mild 12.2% (7/57) 15.7% (9/57) 12.2% (7/57) 
No evidence 0% (0/57) 1.7% (1/57) 1.7% (1/57) 
Homogenous 40.3% (23/57) 24.5% (14/57) 12.2% (7/57) 
Inhomogenous 59.6% (34/57) 75.4% (43/57) 87.7% (50/57) 
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Table 3. 
Results. 
 
 
 
 Reader 1 Reader 2 Reader 3 
Agreement 
Reader - Pathologist 
51/58 46/58 47/58 
Overrated 5.1% (3/58) 6.9% (4/58) 6.9% (4/58) 
 
Underrated 
 
6.9% (4/58) 
 
13.8% (8/58) 
 
12% (7/58) 
 
Diagnostic Accuracy 
 
88% 
 
79% 
 
81% 
 
95% CIs 
 
77% - 95% 
 
67% - 89% 
 
69% - 90% 
 
K value 
 
0.812 
 
0.683 
 
0.715 
 
Interobserver κ value 
overall 
 
With Reader 2: 0.857 
With Reader 3: 0.843 
 
With Reader 1: 0.857 
With Reader 3: 0.905 
 
With Reader 1: 0.843 
With Reader 2: 0.905 
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Consecutive MR Examinations n=301 
 
  
 
Pathology report: different disease 
n=20  
 
 
Previous surgery at other institution 
n=25  
 
 No evidence of synovial mass 
on MR examination 
n=54 
 
 
 MRI was postoperative follow-up 
examination 
n=59 
 
 
 
No MR examination retrieved 
n=33  
 
 
MRI without T2* GRE sequence 
n=52  
 
Study Population 
n=58 
 
 
 
 
Figure 1: Flowchart of study population and patient recruitment. 
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Fig 2. Focal form of TGCT of the knee. 
 
a. sagittal T1 weighted TSE, b. sagittal T2 weighted TSE, c. axial T1 weighted with 
fat suppression after intravenous administration of gadolinium, d. sagittal T1 
weighted after intravenous administration of gadolinium, e. sagittal T2* weighted 
GRE, d. 5 micron section stained with H&E for routine evaluation and Prussian blue 
staining for evaluation of iron deposition. 
 
 
The MR examination shows a rounded mass located in Hoffa’s fat pad of the left 
knee in a 60 year old male patient. The mass shows low signal intensity on T1 and T2 
weighted images and a peripheral signal reduction in the posterior part of the lesion 
 26 
(white arrow) on T2* wieghted GRE image. The tumor histology panel shows 
marginal iron deposition. The observers quantified the amount of blooming artifact as 
grade 1 which corresponded to the quantification of iron deposition assessed on 
pathology. 
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Fig 3. Diffuse form of TGCT of the finger. 
 
a. sagittal T1 weighted TSE, b. sagittal T1 weighted TSE after intravenous 
administration of gadolinium, c. sagittal T1 weighted TSE subtraction sense after 
intravenous administration of gadolinium, d. sagittal T2* weighted GRE, e. axial T2 
weighted TSE, f. axial T1 weighted SPIR after intravenous administration of 
gadolinium, g. 5 micron section stained with H&E for routine evaluation and 
Prussian blue staining for evaluation of iron deposition. 
 
 
The MR examination shows a mass within the flexor tendon sheath of the third finger 
in a 53 year old female patient.. Low signal intensity predominates on T1 and T2 
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weighted images. The T2* weighted GRE sequence shows signal reduction in the 
posterior part of the lesion (white arrow). After contrast administration the lesion 
shows peripheral enhancement. Histology revealed confluent iron deposition. The 
observers described the amount of the blooming artifact as a grade 2 
(moderate/confluent) which corresponded to the pathologist’s evaluation. 
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Fig 4. Diffuse form of TGCT of the knee. 
 
a. sagittal T1 weighted TSE, b. sagittal T2 weighted TSE, c. axial T1 weighted with 
fat suppression after intravenous administration of gadolinium, d. sagittal T1 
weighted after intravenous administration of gadolinium, e. sagittal T2* weighted 
GRE, d. 5 micron section stained with H&E for routine evaluation and Prussian blue 
staining for evaluation of iron deposition. 
 
 
MR images show a diffuse mass affecting the entire knee joint of a 23 year old 
female patient. The largest portion of the tumor is located in the bursa of the 
semimembranous muscle. Histology showed diffuse iron deposition. The observers 
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described the amount of blooming artifact (white arrow) as a grade III 
(massive/diffuse) which corresponded to the pathologist’s assessment. 
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Fig 5. Additional localisations of TGCT on T2* GRE. 
 
a. axial T1 weighted with fat suppression, b. sagittal T2 weighted TSE, c. sagittal T1 
weighted with fat suppression after intravenous administration of gadolinium, d. 
sagittal T2* weighted GRE. 
 
 
The MR examination shows a mass in the anterior joint recess of the ankle in a 40 
year old female patient. The lesion demonstrates low signal intensity on T1 and T2 
weighted images. Note bony erosion at the anterior tibia and talus. The T2* GRE 
weighted image clearly shows an additional nodular manifestation in the posterior 
 32 
joint recess (white arrow), which was not diagnosed on images of the standard 
sequences. 
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Fig 6. Additional findings. 
 
a. sagittal T1 weighted TSE, b. sagittal T2 weighted TSE, c. sagittal T2* weighted 
GRE, d. sagittal T1 weighted TSE, e. sagittal T1 weighted TSE with fat suppression 
after intravenous administration of gadolinium, f. sagittal T2* weighted GRE. 
 
 
Additional findings in patients affected by TGCT are bone erosions at the bare areas, 
subchondral cysts and bone marrow edema. (a-c) The images of the right knee show 
large cystic lesions in the lateral tibial plateau (white arrow) in a 36 year old male 
patient with dffuse type TGCT. (d-f) In the left ankle of a 48 year old female patient 
with diffuse type TGCT in the anterior joint recess pressure erosion at the talar neck 
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and the anterior tibia (black arrows) as well as bone marrow edema of the talus 
(arrowhead) are seen. 
 35 
References 
 
 
 
1. C.D.M. Fletcher, J.A. Bridge, P.C.W. Hogendoorn, F. Mertens, WHO 
Classification of Tumours of Soft Tissue and Bone, Volume 5, fourth ed, 2013, 
pp. 99-103. 
2. H. Jaffe, L. Lichtenstein, C. Sutro, Pigmented villonodular synovitis, bursitis 
and tenosynovitis: a discussion of the synovial and bursal equivalents of the 
tenosynovial lesion commonly denoted as xanthoma, xanthogranuloma, giant 
cell tumor or myeloplaxoma of tendon sheath with some consideration of this 
tendon sheath lesion itself, Arch Pathol. 31 (1941) 731-765. 
3. D.W. Stoller, P.F.J. Tirman, M.A. Bredella, S. Beltran, R.M. Branstetter III, 
 
S.C.P. Blease, Ed Amirsys, Diagnostic Imaging Orthopaedics, first ed. second 
printing June 2004. pp. 90-93,140-143. 
4. S. Ottaviani, X. Ayral, M. Dougados, L. Gossec, Pigmented villonodular 
synovitis: a retrospective single-center study of 122 cases and review of the 
literature, Semin Arthritis Rheum. Jun 40(6) (2011) 539-46. 
5. G.P. Xie, N. Jiang, C.X. Liang, J.C. Zeng, C.Y. Chen, Q. Xu, R.Z. Qi, Y.R. 
Chen, B. Yu, Pigmented villonodular Synovitis: a retrospective multicenter 
study of 237 cases, Plos One. Mar 23,10(3) (2015) e0121451. 
6. R.H. Dorwart, H.K. Genant, W.H. Johnston, J.M. Morris, Pigmented 
villonodular synovitis of synovial joints: clinical, pathologic, and radiologic 
features, AJR Am J Roentgenol. 143 (1984) 877-885. 
 36 
7. S. Khan, C.H. Neumann, L.S. Steinbach, K.D. Harrington, MRI of giant cell 
tumor of the tendon sheath of the hand: a report of three cases, Eur Radiol. 5 
(1995) 467-470. 
8. L. De Beuckeleer, A. De Schepper, F. De Belder, J. Van Goethem, M.C. 
Marques, J. Broeckx et al. Magnetic resonance imaging of localized giant cell 
tumor of the tendon sheath (MRI of localized GCTTS), Eur Radiol. 7 (1997) 
198-201. 
9. J.S. Jelinek, M.J. Kransdorf, J.A. Utz, B.H. Berrey jr, J.D. Thomson, R.D. 
Heekin, et al, Imaging of pigmented villonodular synovitis with emphasis on 
MR imaging, AJR Am J Roentgenol. Feb152(2) (1989) 337-42. 
10. D. Karasick, S. Karasick, Giant cell tumor of tendon sheath: spectrum of 
radiologic findings, Skeletal Radiol. 21(4) (1992) 219-24. 
11. S.J. Lynskey, M.J. Pianta, MRI and thallium features of pigmented 
villonodular synovitis and giant cell tumours of tendon sheaths: a retrospective 
single centre study of imaging and literature review, BR J Radiol. Dec88 
(2015) (1056):20150528. 
12. K.W. Kim, M.H. Han, S.W. Park, S.H. Kim, H.J. Lee, H.J. Jae, et al, 
Pigmented villonodular synovitis of the temporomandibular joint: MR findings 
in four cases, Eur J Radiol. Mar49(3) (2004) 229-34. 
13. J.K. Jelinek, M.J. Kransdorf, B.M. Shmookler, A.A. Aboulafia, M.M. 
Malawer, Giant cell tumor of the tendon sheath: MR findings in nine cases, 
AJR Am J Roentgenol. Apr162(4) (1994) 919-22. 
 37 
14. J. Llauger, J. Palmer, J.M. Monill, T. Franquet, S. Baqué, N. Rosón, MR 
imaging of benign soft-tissue masses of the foot and ankle, Radiographics. 
Nov-Dec18(6) (1998) 1481-98. 
15. J. Llauger, J. Palmer, N. Rosón, R. Cremades, S. Bagué, Pigmented 
villonodular synovitis and giant cell tumors of the tendon sheath: radiologic 
and pathologic features, AJR Am J Roentgenol. 172 (1992) 1087-1091. 
16. J. Lin, J.A. Jacobson, D.A. Jamadar, J.H. Ellis, Pigmented villonodular 
synovitis and related lesions: the spectrum of imaging findings, AJR Am J 
Roentgenol. 172 (1999) 191-197. 
17. T.H. Hughes, D.J. Sartoris, M.E. Schweitzer, D.L. Resnick, Pigmented 
villonodular synovitis: MRI characteristics, Skeletal Radiol. 24 (1995) 7-12. 
18. M.D. Murphey, J.H. Rhee, R.B. Lewis, J.C. Fanburg-Smith, D.J. Flemming, 
 
E.A. Walker, Pigmented villonodular synovitis: radiologic-pathologic 
correlation, Radiographics. 28(5) (2008) 1493-518. 
19. H.W. Garner, C.J. Ortiguera, R.E. Nakhleh, Pigmented Villonodular Synovitis, 
Radiographics. 28 (2008) 1519–1523. 
20. Y. Kitagawa, H. Ito, Y. Amano, T. Sawaizumi, T. Takeuchi, MR imaging for 
preoperative diagnosis and assessment of local tumor extent on localized giant 
cell tumor of tendon sheath, Skeletal Radiology. Nov;32(11) (2003) 633-8. 
21. B.P. Eckhardt, R.J. Hernandez, Pigmented villonodular synovitis: MR imaging 
in pediatric patients, Pediatric Radiology. 34 (2004) 943-947. 
 38 
22. X.G. Cheng, Y.H. You, W. Liu, T. Zhao, H. QU, MRI features of pigmented 
villonodular synovitis (PVNS), Clin Rheumatol. Feb;23(1) (2004) 31-4. 
23. R. Bitar, G. Leung, R. Perng, S. Tadros, A.R. Moody, J. Sarrazin J, et al, MR 
pulse sequences: what every radiologist wants to know but is afraid to ask, 
RadioGraphics. 26 (2006) 513–537. 
24. M.J. Kransdorf, M.D. Murphey, Synovial tumors, In: Imaging of soft tissue 
tumors, Pa: Lippincott Williams & Wilkins, Philadelphia, 2006; 381–436. 
25. H.D. Dorfman, B. Czerniak, Synovial lesions, In: Bone tumors. Mo: Mosby, St 
Louis, 1998; 1061-1071. 
26. K.R. Chin, S.J. Barr, C. Winalski, D. Zurakowski, G.W. Brick, Treatment of 
advanced primary and recurrent diffuse pigmented villonodular synovitis of the 
knee, J Bone Joint Surg Am. 84 (2002) 2192–2202. 
27. E. Palmerini, E.L. Staals, R.G. Maki, S. Pengo, A. Cioffi, M. Gambarotti, et al, 
Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 
294 patients before the era of kinase inhibitors, Eur J Cancer. Jan;51(2) (2015) 
210-7. 
28. H. Sharma, B. Rana, A. Mahendra, M.J. Jane, R. Reid, Outcome of 17 
pigmented villonodular synovitis (PVNS) of the knee at 6 years mean follow- 
up, Knee. Oct;14(5) (2007) 390-4. 
29. D.J. Ogilvie-Harris, J. Mc Lean, M.E. Zarnett, Pigmented villonodular 
synovitis of the knee. The results of total arthroscopic synovectomy, partial, 
 39 
arthroscopic synovectomy, and arthroscopic local excision, J Bone Joint Surg 
Am. Jan;74(1) (1992 ) 119-23. 
30. J.C. Aurégan, S. Klouche, Y. Bohu, N. Lefèvre, S. Herman, P. Hardy, 
Treatment of pigmented villonodular synovitis of the knee, Arthroscopy. 
Oct;30(10) (2014) 1327-41. 
